Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in TGTX — Tg Therapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to TGTX Full portfolio

Position in TGTX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$63,878,371
+$33,739,359 QoQ
Shares Held
1,922,889
+90.2% QoQ
Ownership
1.26%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in TGTX Over Time

Shares Held

Position Value (USD)

Derivatives in TGTX

reported options exposure · as of Mar 31, 2026
CallValue
$10,201,862
CallShares
307,100
PutValue
$7,105,758
PutShares
213,900

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,780,974,653 across 374 Biotechnology names. TGTX ranks #23 (1.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in TGTX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $10,201,862 307,100
2026-03-31 $7,105,758 213,900
2026-03-31 $63,878,371 1,922,889
2025-12-31 $6,671,478 223,800
2025-12-31 $30,139,012 1,011,037
2025-12-31 $11,500,698 385,800
2025-09-30 $35,861,395 992,703
2025-09-30 $13,178,400 364,800
2025-09-30 $11,769,525 325,800
2025-06-30 $17,854,639 496,100
2025-06-30 $37,590,403 1,044,468
2025-06-30 $14,338,416 398,400
2025-03-31 $15,842,974 401,800
2025-03-31 $25,466,929 645,877
2025-03-31 $21,907,308 555,600
2024-12-31 $9,779,490 324,900
2024-12-31 $16,410,520 545,200
2024-12-31 $15,470,196 513,960
2024-09-30 $7,641,513 326,700
2024-09-30 $6,263,842 267,800
2024-09-30 $2,926,884 125,134
2024-06-30 $33,085,699 1,859,792
2024-06-30 $3,301,824 185,600
2024-06-30 $4,431,489 249,100
2024-03-31 $5,315,895 349,500
2024-03-31 $3,356,847 220,700
2024-03-31 $28,569,444 1,878,333
2023-12-31 $7,933,010 464,462
2023-12-31 $11,231,808 657,600
2023-12-31 $6,174,420 361,500
2023-09-30 $3,988,556 477,100
2023-09-30 $2,433,596 291,100
2023-09-30 $3,212,839 384,311
2023-06-30 $4,455,525 179,369
2023-06-30 $16,794,324 676,100
2023-06-30 $9,789,444 394,100
2023-03-31 $5,054,944 336,100
2023-03-31 $16,066,404 1,068,245
2023-03-31 $6,783,040 451,000
2022-12-31 $11,197,095 946,500
2022-12-31 $7,327,502 619,400
2022-12-31 $4,153,512 351,100
2022-09-30 $5,275,904 891,200
2022-09-30 $9,255,179 1,563,375
2022-09-30 $1,740,480 294,000
2022-06-30 $3,174,325 746,900
2022-06-30 $1,564,425 368,100
2022-06-30 $7,299,136 1,717,444
2022-03-31 $3,528,210 371,000
2022-03-31 $6,420,201 675,100

Report a Problem

Category
Description
Email (optional, for follow-up)